Sign in

    Ram Raju

    Managing Director of Equity Research at H.C. Wainwright & Co.

    Ram Selvaraju is a Managing Director of Equity Research at H.C. Wainwright & Co., specializing in healthcare sector analysis with a strong focus on biotechnology and pharmaceuticals. He has covered more than 200 companies including Vanda Pharmaceuticals, Gain Therapeutics, and INOVIO, and is known for his deep expertise and rigorous research, though his recent TipRanks metrics indicate a 31% success rate and an average return of -3.4%. Selvaraju began his professional career at Serono, later transitioning to Rodman & Renshaw, Hapoalim Securities, MLV & Co., and Aegis Capital before joining H.C. Wainwright, accumulating nearly 20 years of Wall Street experience. He holds a Ph.D. in cellular immunology and molecular neuroscience from the University of Geneva, an MBA from Cornell University, and maintains professional credentials in equity research.

    Ram Raju's questions to Protalix BioTherapeutics (PLX) leadership

    Ram Raju's questions to Protalix BioTherapeutics (PLX) leadership • Q1 2025

    Question

    Representing H.C. Wainwright & Co., an analyst asked for confirmation on the FDA regulatory body for ProCellEx products, the potential impact of U.S. pharmaceutical tariffs on cost of goods sold, and whether partner Chiesi has discussed raising Elfabrio's U.S. list price.

    Answer

    Executive Dror Bashan confirmed Elfabrio was approved by the FDA's Rare Disease Division. Executive Eyal Rubin explained that since Protalix sells to its Italian partner Chiesi, the transaction is not directly subject to U.S. tariffs. Rubin also stated that, to their knowledge, Chiesi has not planned a price increase in response to potential tariffs, though this is Chiesi's decision.

    Ask Fintool Equity Research AI